Systemic Lupus Erythematosus: Pathogenesis, Clinical Insights, and the Emerging Role of Serum Amyloid A-to-Albumin Ratio as a Biomarker

Background: Systemic lupus erythematosus (SLE) is a heterogeneous, multisystem autoimmune disease driven by genetic susceptibility, disordered innate–adaptive crosstalk, and environmental triggers. Despite improved classification and targeted therapies, timely assessment of disease activity and prognosis remains challenging, particularly across diverse clinical phenotypes. This article aimed to synthesize current concepts in SLE epidemiology, immunopathogenesis, clinical presentation, and management, and to critically appraise the emerging value of the serum amyloid A-to-albumin ratio (SAR) as a pragmatic biomarker for activity and outcomes. We review key mechanisms including type I interferon signaling, aberrant B/T-cell activation, complement dysfunction, and impaired apoptotic clearance linking them to organ-specific manifestations and contemporary treat-to-target strategies. We then examine evidence positioning SAR, which integrates an acute-phase reactant with a negative inflammatory and nutritional marker (albumin), as a simple, accessible index that may outperform single analytes for detecting flares, stratifying risk, and monitoring therapy. Conclusion: SAR holds promise to complement existing serologies and composite scores, potentially refining real-world SLE monitoring and personalized care.